Phase II Randomized Study of Lisinopril or
Carvedilol Phosphate Extended-Release in Reducing Cardiotoxicity in
Women With HER2-Positive Breast Cancer Receiving Adjuvant or Neoadjuvant
Trastuzumab (Lisinopril/Carvedilol
Phosphate/PLACEBO
Provided)
SCUSF-0806
(MBMC Contact:
Diana Christian 314-996-5888)
Click For Consent
(ONLY
AVAILABLE AT MBMC and RURAL OUTREACHES)
Phase II Randomized Study of
Neoadjuvant Paclitaxel With Versus Without Carboplatin and/or
Bevacizumab Followed by Dose-Dense Doxorubicin Hydrochloride and
Cyclophosphamide in Patients With Hormone Receptor-Poor, HER2-Negative
Resectable Breast Cancer (Bevacizumab Provided)
CALGB 40603
(MBMC Contact: Henry Robinson
314-996-5865)
Click
For Consent
***
(SUSPENDED)
Phase III Randomized Study of
Neoadjuvant Paclitaxel in Combination With Trastuzumab (Herceptin)
and/or Lapatinib Ditosylate in Patients With HER2-Positive Resectable
Stage II or III Breast Cancer (Lapatinib Provided)
CALGB 40601
(MBMC Contact:
Henry Robinson 314-996-5865)
Click
For Consent
***
***Available through CTSU
Next
→